Document is current
Any future updates will be listed below
-
Authors
Schäfer, Arne https://orcid.org/0000-0001-6600-3691
Kovacs, Magdolna Szilvia https://orcid.org/0000-0001-9215-6501
Eder, Anna https://orcid.org/0000-0002-6154-4322
Nigg, Axel https://orcid.org/0000-0001-5805-806X
Feuchtenberger, Martin https://orcid.org/0000-0001-8028-8099
- License Information
-
More Information
Article History
Received: 10 May 2022
Revised: 18 July 2022
Accepted: 5 August 2022
First Online: 15 August 2022
Declarations
:
: All patients provided written informed consent for study participation and publication of the scientific data obtained. This study was approved by the ethics committee of the University Hospital of Würzburg, Würzburg, Germany. The process of organising and conducting the study followed the principles of “Good Clinical Practice” [, ].
: Dr. Schäfer reports personal fees from Amgen, AstraZeneca, and Novo Nordisk Pharma GmbH outside of the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Feuchtenberger reports personal fees from AbbVie, Novartis, Roche, and UCB outside of the submitted work. All authors disclosed financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication.
Free to read: This content has been made available to all.
